

MEDIENINFORMATION

Greifswald, 6. Oktober 2016

400 Ärzte und Wissenschaftler aus aller Welt tagen in Warnemünde Greifswalder Klinikdirektor holt erstmals einen ESC-Kongress nach Mecklenburg-Vorpommern

Vom 13. bis 15. Oktober 2016 findet im Kongresszentrum Hohe Düne in Rostock-Warnemünde ein großer Kongress der Europäischen Gesellschaft für Kardiologie (ESC) statt. Dazu werden in dem Ostseebad ca. 400 Ärzte und Wissenschaftler aus aller Welt erwartet. „Wir freuen uns sehr, dass die bedeutendste kardiologische Fachgesellschaft in Europa erstmals einen Kongress über Herzmuskelerkrankungen in Mecklenburg-Vorpommern ausrichtet“, sagte Prof. Stephan Felix (Foto), Direktor der Klinik und Poliklinik für Innere Medizin B an der Universitätsmedizin Greifswald. Der Greifswalder Kardiologe hatte sich für einen Austragungsort in Mecklenburg-Vorpommern stark gemacht und fungiert auch als Tagungspräsident. Die European Society of Cardiology (ESC) ist die europäische Fachgesellschaft der Kardiologen, die am 2. September 1950 anlässlich des ersten Kardiologie-Weltkongresses in Paris gegründet wurde. Aktuell umfasst die medizinische Fachgesellschaft sechs Dachverbände, 56 nationale Fachverbände sowie 15 Arbeitsgemeinschaften und vereint rund 95.000 Mitglieder (www.escardio.org).

Auf dem Kongress und gleichzeitig der „13. Jahrestagung der Arbeitsgruppe Herzmuskel- und Herzbeutelkrankungen der Europäischen Gesellschaft für Kardiologie“ werden alle relevanten Entwicklungen zu Diagnose- und Therapieverfahren von Herzmuskelerkrankungen und Herzmuskelentzündungen bis hin zur Herzmuskelschwäche vorgestellt und diskutiert. Zu den unterschiedlichen Themen werden renommierte Herzspezialisten aus Europa und den USA Vorträge halten und Kurse anbieten (s. Programm/www.cardiomyopathies2016.com).

„Das Diagnose- und Behandlungsspektrum dieser Krankheiten hat sich in den vergangenen Jahren deutlich erweitert“, betonte der Greifswalder Herzspezialist. „Das betrifft alle Bereiche von der Bildgebung, Histologie, Immunologie, Genetik und Molekularbiologie. Trotzdem besteht auf diesem Gebiet weiterhin noch großer Forschungsbedarf. Dem fachlichen Austausch von klinisch tätigen Ärzten und Grundlagenforschern kommt dabei eine besondere Bedeutung zu“, so Felix. Auch die Greifswalder Kardiologen forschen zu Herzmuskelerkrankungen und sind ein Standort des Deutschen Zentrums für Herz-Kreislauf-Forschung e.V. (DZHK).

Erkrankungen des Herzmuskels schränken die Funktion des Herzens ein. Der Körper wird nicht mehr ausreichend mit Sauerstoff versorgt. Herzmuskelerkrankungen führen zu Herzschwäche (Herzinsuffizienz) und Herzrhythmusstörungen und können deshalb lebensbedrohlich sein. Risikofaktoren sind Entzündungen, Gifte, Alkohol, Bluthochdruck, Herzklappenfehler und ein Herzinfarkt oder auch genetisch bedingte Störungen.

Universitätsmedizin Greifswald
Klinik und Poliklinik für Innere Medizin B
Direktor: Prof. Dr. med. Stephan Felix
Sauerbruchstraße, 17475 Greifswald
T +49 3834 86-80 500
E InnereB@uni-greifswald.de
www.medizin.uni-greifswald.de
www.facebook.com/UnimedizinGreifswald
Twitter @UMGreifswald



13th Meeting of the Working Group on Myocardial and Pericardial Diseases of the European Society of Cardiology

October, 13 – 15, 2016
Rostock-Warnemünde



13th Meeting of the ESC
Working Group on Myocardial
and Pericardial Diseases



Organizing Committee:
Prof. S. Felix, Prof. A. Caforio, Prof. A. Linhart

Organizer: C.T.I. GmbH

Location: Hotel Hohe Düne



**FROM THE SYMPOSIUM DIRECTORS AND THE
CHAIRPERSON OF THE MYOCARDIAL AND
PERICARDIAL DISEASE WORKING GROUP OF THE
EUROPEAN SOCIETY OF CARDIOLOGY**

Dear colleagues,

It is a particular pleasure for us to welcome you to the 13th Meeting of the Myocardial and Pericardial Diseases Working Group of the European Society of Cardiology, to be held in Warnemuende on October 13 – 15, 2016.

Cardiomyopathies and pericardial diseases increasingly occupy cardiologists in clinical and general practice. The diagnostic spectrum of these diseases has markedly expanded during the last decade and encompasses imaging, histology, immunology, genetics and molecular biology. Likewise, treatment of cardiomyopathies is still a major challenge for the attending physicians and requires further research efforts.

For the program of this meeting, we tried to balance between basic and clinical science and we also considered the broad field of diagnostics and therapy of heart failure. As in the previous meetings of our working group, the main program is preceded by practice-oriented **Mini-courses** with **How-to sessions** and case study presentations. Again, novel options in clinical and basic research such as next generation genetic testing, non-coding genome in myocar-

dial disease, gene therapy and innovative pharmacological approaches for heart failure treatment as well as device therapy will be discussed. The congress program will cover all relevant practical and scientific aspects of this challenging field including introduction of innovative diagnostic and therapeutic procedures. We hope that the broad range of topics will attract the interest of a wide audience, including physicians, clinical researchers, cardiologists, pathologists, basic scientists, and young investigators. The congress also aims to stimulate further research in the topics of our Working group.

We cordially welcome you to the meeting in Warnemünde and wish all of you informative and exciting days as well as open and stimulating discussions and new insights for all research activities and the mutual care of our patients.

We look forward to seeing you in Warnemuende at the coast of the Baltic Sea in October.

Prof. S. Felix

Prof. A. L. P. Caforio

Prof. A. Linhart



Program

Day 1 • 13 October 2016

12:00–14:00 **Nucleus Meeting of WG on Myocardial and Pericardial Disease**

08:30–16:30 Concurrent minicourses:

How-to session for young cardiologists: Differential diagnosis and management in the cardiomyopathies (extra educational mini-course 1)

Chairs: *E. Biagini, A. Linhart*

08:30–08:50 **A clinical case of sarcomeric HCM – How to reach the diagnosis and how to manage**

A. Milandri

08:50–09:10 Interactive discussion with the audience and chairs

09:10–09:30 **Guidance to genetic analysis and genetic counseling**

L. Monserrat

09:30–09:50 Interactive discussion with the audience and chairs

09:50–10:10 **The red flags approach in sarcomeric HCM: Take home messages**

E. Biagini

10:10–10:30 Coffee break

10:30–10:50 **A clinical case of non-sarcomeric HCM – How to reach the diagnosis**

D. Rob

10:50–11:10 Interactive discussion with the audience and chairs

11:10–11:30 **A clinical case of non sarcomeric HCM – How to manage**

J. Marek

11:30–11:50 Interactive discussion with the audience and chairs

11:50–12:10 **The red flags approach in non-sarcomeric HCM: Take home messages**

A. Linhart

12:10–13:00 Lunch

Chairs: *P. Garcia-Pavia, A. Keren*

13:00–13:20 **A clinical case of restrictive familial cardiomyopathy – How to reach the diagnosis**

E. Gonzalez-Lopez

13:20–13:40 Interactive discussion with the audience and chairs



Program

Day 1 • 13 October 2016

- 13:40–14:00 **A clinical case of restrictive familial cardiomyopathy – How to manage**
E. Gonzalez-Lopez
- 14:00–14:20 Interactive discussion with the audience and chairs
- 14:20–14:40 **The red-flag approach in restrictive familial cardiomyopathy: Take home messages**
P. Garcia-Pavia
- 14:40–15:00 **A clinical case of restrictive non-familial cardiomyopathy – How to reach the diagnosis**
A. Turyan Medvedovsky
- 15:00–15:20 Interactive discussion with the audience and chairs
- 15:20–15:40 **A clinical case of restrictive non-familial cardiomyopathy – How to manage**
A. Turyan Medvedovsky
- 15:40–16:00 Interactive discussion with the audience and chairs
- 16:00–16:20 **The red flags approach in restrictive non-familial cardiomyopathy: Take home messages**
A. Keren

**How-to session for young cardiologists:
Interventional procedures in inflammatory /
infectious myocardial and pericardial disease**

(extra educational minicourse 2)

Chairs: A. Frustaci, K. Klingel

- 08:30–08:50 **A clinical case of clinically suspected infectious myocarditis – How to reach the diagnosis**
C. Chimenti
- 08:50–09:10 Interactive discussion with the audience and chairs
- 09:10–09:30 **A clinical case of biopsy-proven infectious myocarditis – How to manage**
C. Chimenti
- 09:30–09:50 Interactive discussion with the audience and chairs
- 09:50–10:10 **The EMB work-up of infectious and non infectious myocarditis: Take home messages from the pathologist**
K. Klingel
- 10:10–10:30 Coffee break



Program

Day 1 • 13 October 2016

- | | | | |
|-------------------------------------|--|-------------|---|
| 10:30–10:50 | A clinical case of clinically suspected non infectious myocarditis – How to reach the diagnosis
<i>I. Kindermann</i> | 13:40–14:00 | A clinical case of Cardiac tamponade – How to manage
<i>I. Milinkovic</i> |
| 10:50–11:10 | Interactive discussion with the audience and chairs | 14:00–14:20 | Interactive discussion with the audience and chairs |
| 11:10–11:30 | A clinical case of biopsy-proven non infectious myocarditis – How to manage
<i>I. Kindermann</i> | 14:20–14:40 | Cardiac tamponade and pericardial biopsy: Take home messages from the interventional cardiologist
<i>A. Ristic</i> |
| 11:30–11:50 | Interactive discussion with the audience and chairs | 14:40–15:00 | A clinical case of refractory recurrent pericarditis – How to reach the diagnosis
<i>A. Battaglia</i> |
| 11:50–12:10 | The clinical and diagnostic role of EMB: Take home messages from the interventional cardiologist
<i>A. Frustaci</i> | 15:00–15:20 | Interactive discussion with the audience and chairs |
| 12:10–13:00 | Lunch | 15:20–15:40 | A clinical case of refractory recurrent pericarditis – How to manage
<i>A. Battaglia</i> |
| Chairs: M. Imazio, A. Ristic | | 15:40–16:00 | Interactive discussion with the audience and chairs |
| 13:00–13:20 | A clinical case of Cardiac tamponade – How to reach the diagnosis
<i>I. Milinkovic</i> | 16:00–16:20 | Refractory recurrent pericarditis and chronic pericardial effusions: Take home messages from the clinical cardiologist
<i>M. Imazio</i> |
| 13:20–13:40 | Interactive discussion with the audience and chairs | | |



Program

Day 1 • 13 October 2016

How-to session for young cardiologists: Integrated cardiovascular imaging in the cardiomyopathies

(extra educational mini-course 3)

Chairs: *M. Arad, R. Strasser*

- 08:30–08:50 **A clinical case of clinically suspected storage cardiomyopathy – How to reach the diagnosis**
F. Heidrich
- 08:50–09:10 Interactive discussion with the audience and chairs
- 09:10–09:30 **A clinical case of proven storage cardiomyopathy – How to manage**
F. Heidrich
- 09:30–09:50 Interactive discussion with the audience and chairs
- 09:50–10:10 **Role of CMR in diagnosis and management of storage cardiomyopathies: When is it the gold standard? Take home messages**
R. Strasser
- 10:10–10:30 Coffee break

- 10:30–10:50 **A clinical case of clinically suspected metabolic cardiomyopathy – How to reach the diagnosis**
D. Lotan
- 10:50–11:10 Interactive discussion with the audience and chairs
- 11:10–11:30 **A clinical case of clinically suspected metabolic cardiomyopathy – How to manage**
D. Lotan
- 11:30–11:50 Interactive discussion with the audience and chairs
- 11:50–12:10 **Metabolic cardiomyopathies made simple: Take home messages from the clinical cardiologist**
M. Arad
- 12:10–13:00 Lunch



Program

Day 1 • 13 October 2016

Chairs: *G. Limongelli, K. Wahbi*

13:00–13:20 **A clinical case of suspected cardiomyopathy with associated myopathy in the adult – How to reach the diagnosis**

M. Sochala

13:20–13:40 Interactive discussion with the audience and chairs

13:40–14:00 **A clinical case of cardiomyopathy with associated myopathy in the adult – How to manage**

M. Sochala

14:00–14:20 Interactive discussion with the audience and chairs

14:20–14:40 **Cardiomyopathies with associated myopathies in the adult: Differential diagnosis and take-home messages**

K. Wahbi

14:40–15:00 **A clinical case of cardiomyopathy with associated myopathy in the pediatric age – How to reach the diagnosis**

D. Masarone

15:00–15:20 Interactive discussion with the audience and chairs

15:20–15:40 **A clinical case of cardiomyopathy with associated myopathy in the pediatric age – How to manage**

D. Masarone

15:40–16:00 Interactive discussion with the audience and chairs

16:00–16:20 **Cardiomyopathies with associated myopathies in the pediatric age: Differential diagnosis and take-home messages**

G. Limongelli



Program

Day 1 • 13 October 2016

Program

Plenary room

- 16:45–17:00 **Official opening: Welcome by Scientific directors and by the Myocardial and Pericardial Diseases ESC Working Group**
Chairs: *A. L. Caforio, A. Linhart*
- 16:45–19:30 **Session 1**
Inaugural session (educational session 1)
Diagnosis of cardiomyopathies
Chairs: *A. L. Caforio, S. B. Felix*
- 17:00–17:25 **Definition and classification – An overview**
Genetic testing is superior to biopsy of the myocardium in cardiomyopathy
Y. Pinto
- 17:25–17:50 **Pro**
H. Katus
- 17:50–18:15 **Contra**
H.-P. Schultheiss
- 18:15–18:40 **Advances in imaging: Echocardiography, MRI, CT and PET – What is essential for diagnostic work-up?**
A. Linhart
- 18:40–19:05 **The MOGE(S) Classification for a phenotype-genotype nomenclature of cardiomyopathy**
E. Arbustini
- 19:05–19:30 **Prognostic Relevance of gene-environment interactions in patients with dilated cardiomyopathy**
S. Heymans

Day 2 • 14 October 2016

Plenary room

- 08:30–10:10 **Session 2**
Personalized medicine for diagnosis and treatment of myocarditis and inflammatory cardiomyopathy
(educational session 2)
Chairs: *A. Anastasakis, R. Jahns*
- 08:30–08:55 **Diagnostic work up in myocarditis and DCM**
M. Dörr
- 08:55–09:20 **Endomyocardial biopsy is essential for diagnosis**
K. Klingel
- 09:20–09:45 **Role of cardiovascular magnetic resonance**
J. Schulz-Menger
- 09:45–10:10 **From evidence-based treatment to future direction for research in inflammatory cardiomyopathy**
U. Eriksson
- 10:10–10:40 **Coffee break**



Program

Day 2 • 14 October 2016

08:30–10:30 **Concurrent Session 2**
Hypertrophic cardiomyopathy: From bench to bedside (educational session 3)
Chairs: *P. Elliott, A. Rigopoulos*

08:30–08:50 **Stepwise approach for risk stratification**
P. Elliott

08:50–09:10 **Next generation genetic testing – What next:**
J. Mogensen

09:10–09:30 **Gene therapy for inherited sarcomeric pediatric cardiomyopathy**
L. Carrier

09:30–09:50 **Evidence-based medical treatment**
J. Olivotto

09:50–10:10 **Evidence-based percutaneous gradient ablation**
H. Seggewiss

10:10–10:30 **Surgical therapies**
P. Ferrazzi

10:30–11:00 **Coffee break**

Plenary room

10:40–12:35 **Session 3**
Myocardial involvement in systemic immune-mediated diseases: Focus on the myocardial and pericardial disease Position paper (educational session 4)
Chairs: *E. Arbustini, A. L. Caforio*

10:40–11:05 **Systemic autoimmune diseases and cardiac involvement: Focus on animal models and common mechanisms**
V. Poli

11:05–11:30 **What's new: The cardiac pathologist's point of view**
C. Basso

11:30–11:55 **What's new: The cardiologist's point of view**
S. B. Felix

11:55–12:20 **What's new: The immunologist's point of view**
R. Marcolongo

12:20–12:35 **What next:**
U. Eriksson

12:35–14:00 **Lunch**



Program

Day 2 • 14 October 2016

11:00–13:30 **Concurrent Session 3**
The Noncoding genome in myocardial diseases – Pathogenic implications and therapeutic perspectives for the cardiomyopathies (extra-educational session 4)
Chairs: *M. Arad, P. Charron*

11:00–11:25 **Noncoding RNAs in cardiovascular disease – Status of clinical translation**
T. Thum

11:25–11:50 **MicroRNAs in cardiac fibrosis and hypertrophy**
S. Engelhardt

11:50–12:15 **Monocyte-directed RNAi in cardiac inflammation**
F. Leuschner

12:15–12:40 **Gene editing**
J.-S. Hulot

12:40–13:05 **Methylome**
B. Meder

13:05–13:30 **Gene and microRNA based therapies for heart failure**
Status of clinical translation
R. Hajjar

13:30–14:30 **Lunch**

Plenary room

14:00–17:55 **Session 4**
Diastolic and systolic dysfunction in heart failure and the cardiomyopathies – From diagnosis to treatment (extra educational session 5)
Chairs: *M. Fu, A. Ristic*

14:00–14:25 **Stepwise diagnostic approach**
C. Tschöpe

14:25–14:50 **Current evidence on treatment of patients with chronic systolic heart failure**
A. Ristic

14:50–15:15 **Immunoabsorption as a treatment option in DCM**
S. B. Felix

15:15–15:40 **Cardiac implantable electronic devices in systolic heart failure**
M. Busch

15:40–16:05 **Systolic heart failure: New drugs in the pipeline**
B. Pieske

16:05–16:30 **Coffee break**



Program

Day 2 • 14 October 2016

- 16:30–16:55 **New treatment options for diastolic dysfunction**
G. Hasenfuß
- 16:55–17:55 **Keynote Lecture**
Myocardial regeneration in the cardiomyopathies – A therapeutic option?
- Basic research**
T. Eschenhagen
- Clinical trials**
S. Janssens

- 14:30–18:20 **Concurrent Session 4**
Rare myocardial diseases – From diagnosis to treatment
(educational session 5)
Chairs: *A. L. Caforio, H. Madeira*
- 14:30–14:55 **Pediatric diseases**
G. Limongelli
- 14:55–15:20 **Anderson-Fabry disease**
A. Linhart
- 15:20–15:45 **Glycogen storage disease**
M. Arad
- 15:45–16:10 **Amyloidosis**
C. Rapezzi
- 16:10–16:35 **Neuro-muscular disease**
A. Pantazis
- 16:35–16:55 **Coffee break**
- 16:55–17:20 **Inflammatory cardiomyopathies**
C. Basso
- 17:20–18:20 **Keynote Lecture**
Rare cardiomyopathies-challenges and opportunities
P. Elliott



Program

Day 3 • 15 October 2016

Plenary room

08:30–09:30 **Session 5**
Diagnosis and treatment of pericardial diseases – Focus on the 2015 Guidelines (educational session 6)
Chairs: *S. Pankuweit, A. Ristic*

08:30–08:55 **Clinical and diagnostic work-up**
B. Maisch

08:55–09:20 **Medical treatment**
M. Imazio

09:20–09:30 **What next:**
Y. Adler

09:30–09:45 **Young Investigator Awards**

09:45–10:05 **Coffee break**

10:05–12:35 **Session 6**
Acute decompensated chronic heart failure – A diagnostic and therapeutic challenge in cardiomyopathies of different aetiologies (educational session 7)
Chairs: *S. Blankenberg, A. Keren*

10:05–10:30 **The diagnostic accuracy of the natriuretic peptides in heart failure**
J. Mant

10:30–10:55 **New drugs for treatment of acute decompensated heart failure**
V. Mitrovic

10:55–11:20 **Ultrafiltration in patients with acute decompensated chronic heart failure**
G. Marezi

11:20–11:45 **Impella ventricular support in patients with cardiogenic shock**
M. Ferrari

11:45–12:10 **Emergency extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock**
S. Beurtheret

12:10–12:35 **Keynote Lecture**
Auto-immune mechanisms in myocarditis and dilated cardiomyopathy
A. L. Caforio



Program

Day 3 • 15 October 2016

- 10:05–12:15 **Concurrent Session 6**
Arrhythmogenic cardiomyopathies
(educational session 8)
Chairs: *A. Anastasakis, P. Elliott*
- 10:05–10:30 **Genetic diagnosis – An update for the clinician**
E. Arbustini
- 10:30–10:55 **Pathology – Still the gold standard?**
C. Basso
- 10:55–11:20 **Clinical and non-invasive work-up**
A. Tsatsopoulou
- 11:20–11:45 **Risk stratification**
T. Wichter
- 11:45–12:15 **Keynote Lecture**
Treatment of ARVC: Key messages from the international and future perspectives
D. Corrado

General Information

Organizing Committee

Alida Caforio
Stephan Felix
Aleš Linhart

Conference chair

Prof. Dr. Stephan Felix
University Medicine Greifswald
Department of Internal Medicine B

Organizer

C.T.I. GmbH
Am Bärenkamp 33, 40589 Düsseldorf
Danijela Soulis
dsoulis@cti-kongresse.com
Phone + 49 211 75 20 12

Congress venue

Hotel Hohe Düne
Am Yachthafen 1, 18119 Rostock-Warnemünde
www.hohe-duene.de

Conference language

English is the official language.

Posters

Posters will be displayed during the whole period of scientific sessions.

Registration

<http://www.cardiomyopathies2016.com/>



Faculty (invited)

Yehuda Adler, Ramat Gan IL
Yannick Allanore, Paris FR
Aris Anastasakis, Athens GR
Michael Arad, Ramat Gan IL
Eloisa Arbustini, Pavia IT
Cristina Basso, Padua IT
Alberto Battaglia, Turin IT
Sylvain Beurtheret, Paris FR
Elena Biagini, Bologna IT
Stefan Blankenberg, Hamburg DE
Mathias Busch, Greifswald DE
Alida L.P. Caforio, Padua IT
Lucie Carrier, Hamburg DE
Philippe Charron, Paris FR
Cristina Chimenti, Rome IT
Domenico Corrado, Padua IT
Marcus Dörr, Greifswald DE
Perry Elliott, London UK
Stefan Engelhardt, Munich DE
Urs Eriksson, Wetzikon CH
Thomas Eschenhagen, Hamburg DE
Stephan B. Felix, Greifswald DE
Markus Ferrari, Wiesbaden DE
Paolo Ferrazzi, Monza IT
Andrea Frustaci, Rome IT
Michael Fu, Göteborg, SE
Pablo García Pavía, Madrid ES
Esther Gonzalez Lopez, Madrid ES
Roger Hajjar, New York USA
Gerd Hasenfuß, Göttingen DE
Felix Heidrich, Dresden DE
Stephane Heymans, Maastricht NL
Jean-Sébastien Hulot, Paris FR
Massimo Imazio, Turin IT
Roland Jahns, Würzburg DE
Stefan Janssens, Leuven BE
Hugo Katus, Heidelberg DE
Andre Keren, Jerusalem IL
Ingrid Kindermann, Homburg DE
Karin Klingel, Tübingen DE

Florian Leuschner, Heidelberg DE
Giuseppe Limongelli, Naples IT
Aleš Linhart, Prague CZ
Dor Lotan, Ramat Gan IL
Hugo Madeira, Lisbon PT
Bernhard Maisch, Marburg DE
Jonathan Mant, Cambridge UK
Renzo Marcolongo, Padua IT
Josef Marek, Prague CZ
Giancarlo Menzi, Milan IT
Daniele Masarone, Naples IT
Benjamin Meder, Heidelberg DE
Agnese Milandri, Bologna IT
Ivan Milinkovic, Belgrade RS
Veselin Mitrovic, Bad Nauheim DE
Jens Mogensen, Odense DK
Lorenzo Monserrat, Madrid ES
Iacopo Olivetto, Florence IT
Sabine Pankuweit, Marburg DE
Antonis Pantazis, London UK
Burkert Pieske, Berlin DE
Yigal Pinto, Amsterdam NL
Valeria Poli, Turin IT
Claudio Rapezzi, Bologna IT
Angelos Rigopoulos, Schweinfurt DE
Arsen Ristic, Belgrade RS
Daniel Rob, Prague CZ
Heinz-Peter Schultheiss, Berlin DE
Jeannette Schulz-Menger, Berlin DE
Petar Seferović, Belgrade RS
Hubert Seggewiss, Schweinfurt DE
Maximilien Sochala, Paris FR
Ruth Strasser, Dresden DE
Thomas Thum, Hannover DE
Adalena Tsatsopoulou, Naxos GR
Carsten Tschöpe, Berlin DE
Anna Turyan Medvedovsky, Jerusalem IL
Karim Wahbi, Paris FR
Thomas Wichter, Osnabrück DE



Sponsoring Partners

Novartis Pharma GmbH



Health in Code



Bayer Vital GmbH



Science For A Better Life

HeartWare GmbH



Berlin-Chemie AG



BERLIN-CHEMIE
MENARINI

Maquet Vertrieb und
Service Deutschland GmbH

GETINGE GROUP

Boston Scientific Medizintechnik GmbH

Boston
Scientific

Orion Pharma GmbH



Fresenius Medical Care
Deutschland GmbH



FRESENIUS
MEDICAL CARE

Servier Deutschland GmbH



Medtronic GmbH

Medtronic
Further. Together

Xenios AG



Shire International GmbH

Shire

Siemens Healthcare GmbH



St. Jude Medical GmbH



ST. JUDE MEDICAL

Abiomed Europe GmbH



Transparency / Transparenz

Gemäß FSA-Kodex geben wir die Höhe der Beteiligung folgender Unternehmen für die Einräumung von Werberechten und Standfläche im Rahmen der Veranstaltung bekannt: Bayer Vital GmbH € 15.000; Berlin-Chemie AG € 10.000; HeartWare GmbH € 3.000; Novartis Pharma GmbH € 30.000; Orion Pharma GmbH € 3.000; Servier Deutschland GmbH € 3.000; Shire International GmbH € 15.000; St. Jude Medical GmbH € 10.000; Xenios AG € 3.000

